Nisa Investment Advisors LLC Sells 2,113 Shares of Moderna, Inc. (NASDAQ:MRNA)

Nisa Investment Advisors LLC trimmed its holdings in Moderna, Inc. (NASDAQ:MRNA) by 14.2% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 12,778 shares of the company’s stock after selling 2,113 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Moderna were worth $531,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Intrinsic Value Partners LLC lifted its position in shares of Moderna by 91.1% during the third quarter. Intrinsic Value Partners LLC now owns 51,392 shares of the company’s stock worth $3,435,000 after purchasing an additional 24,505 shares in the last quarter. Banco Santander S.A. acquired a new position in Moderna during the 3rd quarter worth $3,550,000. John G Ullman & Associates Inc. boosted its position in Moderna by 341.3% in the 3rd quarter. John G Ullman & Associates Inc. now owns 49,650 shares of the company’s stock valued at $3,318,000 after buying an additional 38,400 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. increased its stake in shares of Moderna by 11.6% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,614,313 shares of the company’s stock valued at $107,885,000 after buying an additional 167,596 shares during the period. Finally, Vontobel Holding Ltd. raised its position in shares of Moderna by 148.2% during the third quarter. Vontobel Holding Ltd. now owns 116,088 shares of the company’s stock worth $7,758,000 after acquiring an additional 69,313 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Insider Buying and Selling at Moderna

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the sale, the insider now directly owns 19,717 shares of the company’s stock, valued at $843,690.43. This represents a 6.71 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last 90 days, insiders sold 2,664 shares of company stock worth $115,210. 15.70% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Hsbc Global Res upgraded Moderna from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 18th. HSBC upgraded shares of Moderna from a “hold” rating to a “buy” rating and set a $58.00 price target for the company in a research report on Monday, November 18th. Barclays cut their price objective on shares of Moderna from $125.00 to $111.00 and set an “overweight” rating on the stock in a report on Friday, November 8th. JPMorgan Chase & Co. lowered their target price on shares of Moderna from $59.00 to $45.00 and set an “underweight” rating for the company in a report on Tuesday, November 26th. Finally, Evercore ISI cut their price target on Moderna from $60.00 to $50.00 and set an “in-line” rating on the stock in a research note on Monday. Four investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Moderna presently has an average rating of “Hold” and an average price target of $69.79.

Moderna Price Performance

Moderna stock opened at $44.94 on Wednesday. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. Moderna, Inc. has a one year low of $31.94 and a one year high of $170.47. The stock’s 50 day moving average is $40.79 and its 200 day moving average is $62.18. The firm has a market cap of $17.29 billion, a P/E ratio of -7.72 and a beta of 1.60.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.89) by $1.92. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The business had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.25 billion. During the same period in the previous year, the company posted ($1.39) earnings per share. The firm’s revenue for the quarter was up 3.8% on a year-over-year basis. As a group, research analysts expect that Moderna, Inc. will post -9.27 EPS for the current year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.